Impact of Fortetropin
Evaluation of Fortetropin in Geriatric and Senior Dogs With Reduced Mobility
Groundbreaking Study is a Game Changer for Senior Dogs
- Sarcopenia and Osteoarthritis (OA) negatively impact the mobility and quality of life of dogs.
- Fortetropin supplementation showed mild, but statistically significant, improvement of the mobility scores for the treatment group at both week 6 (P = 0.03) and week 12 (P = 0.006) compared to the baseline score. No statistical improvement was noted at any time in the placebo group or between the treatment and placebo group.
- Reducing sarcopenia through Fortetropin supplementation can be a valuable component of a multimodal strategy to treat reduced mobility in geriatric dogs.